Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

REVEAL AF STUDY ICM EVIDENCE FOR SUSPECTED AF

REVEAL AF Study for insertable cardiac monitor use in patients at high risk for atrial fibrillation and stroke

THE REVEAL AF STUDY1

The REVEAL AF Study demonstrates the need for continuous, long-term monitoring with Reveal LINQ™ insertable cardiac monitoring (ICM) in patients at high risk for atrial fibrillation and stroke.

KEY FINDINGS

Reveal AF Study Results Chart

Reveal AF Study Key Findings Chart

INFORM YOUR CLINICAL DECISIONS

There was no significant difference in detection rates between patients with CHADS2 2, 3, and 4 or more.

Reveal AF Study CHADS Chart

CLINICAL IMPACT: MORE APPROPRIATE CARE

Reveal AF Study Secondary End Points


Reveal AF Study Quote

STUDY DESIGN

  • Prospective, global, multicenter study
  • 446 patients enrolled, 385 patients received a Reveal™ ICM and were included in the analysis cohort
  • Patients were followed for an average of 22.5 months + 7.7 months

PATIENT INCLUSION CRITERIA

  • A CHADS2 score of ≥ 3 or CHADS2 = 2 and at least 1 of the following:
  • Coronary artery disease
  • Renal impairment (GFR 30-60 ml/min)
  • Sleep apnea
  • Chronic obstructive pulmonary disease
  • No AF found after 24 hours of cardiac monitoring

END POINTS

Primary

  • Determine the incidence rate of AF lasting ≥ 6 minutes in patients who are at high risk of having AF and stroke.

Secondary

  • Identify predictors of AF onset
  • Characterize the timing and nature of clinical actions relative to detection of AF
1

Reiffel JA, Verma A, Kowey PR, et al. High Incidence of Previously Unknown (“Silent”) Atrial Fibrillation in Patients at High Risk for Atrial Fibrillation and Stroke: Primary Results from the REVEAL AF Study. Abstract presented at Heart Rhythm Society Annual Scientific Sessions. 2017.